The UK is assessing whether to join an EU programme to help secure a potential coronavirus vaccine in what could mark a bellwether for post-Brexit cooperation.
In what the Daily Express described as a “Brexit backtrack”, UK officials are thought to be considering the advantages of being part of the EU plan because the bloc would have greater purchasing power to strike deals with multinational drug companies.
Whether the benefits would outweigh a broader political desire to cut ties with Brussels is reportedly still being evaluated.
The UK has already secured a bilateral deal with AstraZeneca, which is based in Cambridge, but there are fears that some initial vaccines may not be effective and the UK reserves the right to be involved in all projects in the EU’s 2020 budget.
Source: The Guardian